OLANZAPINE

Course overview

OLANZAPINE IS A SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTIC MEDICATION. THE FDA HAS APPROVED THIS MEDICATION FOR SCHIZOPHRENIA IF THE PATIENT IS OVER THE AGE OF 13 AND BIPOLAR DISORDER, INCLUDING MIXED OR MANIC EPISODES. OLANZAPINE IS ALSO APPROVED FOR USE WITH FLUOXETINE, A SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI), IN PATIENTS WITH EPISODES OF DEPRESSION ASSOCIATED WITH BIPOLAR DISORDER TYPE 1 AND TREATMENT-RESISTANT DEPRESSION. IT IS IMPORTANT TO NOTE THAT OLANZAPINE IS NOT FDA-APPROVED FOR PATIENTS UNDER THE AGE OF 13. IN ADDITION, THE COMBINATION OF OLANZAPINE WITH FLUOXETINE IS NOT APPROVED FOR PATIENTS UNDER THE AGE OF 10. THIS ACTIVITY COVERS OLANZAPINE, INCLUDING MECHANISM OF ACTION, PHARMACOLOGY, ADVERSE EVENT PROFILES, ELIGIBLE PATIENT POPULATIONS, CONTRAINDICATIONS, AND MONITORING, AND HIGHLIGHTS THE ROLE OF THE INTERPROFESSIONAL TEAM IN THE MANAGEMENT OF OLANZAPINE THERAPY.